Summary: In this study, the feto-placental transfer or excretion into the milk of motilin Hse), a new human motilin analogue, were assessed after single intravenous injection of gestation or lactat ing female rats with 3H-SK-896.
Introduction

SK-896
(Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu Gln-Arg Leu Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly Gln Hse) is a new human motilin analogue in which leucine replaces methionine at position 13 of human motilin and homoserine is added at the C-terminal. The pharmaco logical profiles of SK-896 in vitro') and in vivo study2 lead us to expect that SK-896 would be useful and effec tive for the treatment of gastroparalysis after abdominal surgery and for diabetes.
The aim of this study was to investigate the feto placental transfer and excretion into the milk of SK-896 in female rats after single intravenous administrations of 3H-SK-896 .
Materials and Methods
Materials
SK-896 ([Leu13]motilin-Hse) was synthesized at Sanwa Kagaku Kenkyusho, Co., Ltd. 3H-SK-896 (Tyr 3,5-3H; Phe-Val-Pro-Ile-Phe-Thr-Tyr [3,5 3H ]-Gly-Glu Leu-Gln-Arg-Leu Gln-Glu Lys-Glu-Arg-Asn-Lys Gly Gln-Hse, 325.8 MBq/mg, 97.7%) was purchased from Daiichi Pure Chemical Co., Ltd (Ibaragi, Japan). Rabbit anti-human motilin serum was prepared by our laborato ry. The antiserum was shown to react mainly with the C terminal portion of SK-896 but never with other known gastrointestinal hormones. Aprotinin (Sigma Chemical Co., USA), Tween 80 (Katayama Chemical Industries, Ltd, Tokyo, Japan), goat anti-rabbit IgG (ICN Pharma ceuticals, Inc.-Cappel products, USA), albumin bovine fraction V (Sigma Chemical Co.) and oxytocin (Teikoku Hormone Mfg. Co., Ltd., Tokyo, Japan) were also used. All other chemicals were of reagent grade.
Animals
Female Sprague-Dawley (SD) rats (SLC Inc., Shizuo ka, Japan), mated at 9 weeks age were used on the 12th and 18th day of gestation and on 14th day after delivery. Their body weight was 224-264 g, 264-304 g and 276 304 g, respectively. The rats were housed in an air-con ditioned room at 22 ± 3°C with relative humidity of 55 ± 15% and a 12-h light cycle, fed a standard laboratory diet (CRF-1; Oriental Yeast, Co., Ltd., Tokyo, Japan) and given water ad libitum. Except for the study on transfer of 3H-SK-896 into milk, rats were fasted over night prior to administration and fed again thereafter 4 h after dosing. The animals used 24 h after dosing were fasted again from 16 h before the experiment started.
Preparation
of Dosing Solution The dosing solution was prepared by diluting an ap propriate amount of 3H-SK-896 stock solution (200 ug/ ml or 2.00 mg/ml) with physiological saline. 3H-SK-896 was diluted by non-labeled SK-896 as needed. The radiochemical purity of the dosing solution was con firmed according to the methods in a previous report.
3 ) The appliances used to prepare the dosing solution and administration were coated with 1% Tween 80 solution to prevent adsorption of 3H-SK-896.
Whole-Body Autoradiography
For the whole-body autoradiography study, female rats on the 12th and 18th day of gestation were given an intravenous bolus of 3H-SK-896 at 100 ug/kg (32.6 MBq/kg) via the tail vein. Rats were sacrificed by ether anaesthesia 2, 30 min and 24 h afer administration. For ty-um thick sections were prepared according to the methods in a previous report.') The sections were placed in contact with X-ray film (MRAG 3H Type; Konica), which was exposed at 4°C for 7 weeks and developed to prepare whole-body autoradiograms.
Feto-Placental Transfer Study
For the feto-placental transfer study, female rats on the 12th and 18th day of gestation were given an in travenous bolus of 4ug/kg (0.260 MBq/kg). Rats were sacrificed by exsanguination from the abdominal aorta under ether anaesthesia 2, 30 min, and 24 h after dosing, and the designated organs and tissues were obtained from the maternal bodies and fetus. Blood samples were collected on an EDTA anticoagulant. After aliquots of blood were taken for total radioactivity measurement, plasma was immediately separated from blood by cen trifugation.
For determination of immunoreactive radioactivity in maternal and fetal plasma, 3H-SK-896 was administered to separate group of rats on the 18th day of gestation at 4 ug/kg (1.30 MBq/kg) for intravenous bolus injection. In this group, aprotinin was added to blood for a final con centration of 1000 kallikrein inactivator units (KIU) /ml.
Each organ or tissue was weighed in whole or part (50-300 mg), and total radioactivity was measured. Plasma immunoreactive radioactivity was also measured using the method described below.
Milk Transfer Study
For the milk transfer study, lactating rats were given an intravenous bolus of 4ug/kg (1.30 MBq/kg). Milk and blood were serially collected 2 (blood only), 5, 15, 30 min and 1, 2, 4, 6 and 24 h after dosing under light ether anaesthesia. Blood samples were collected from the jugular vein on an EDTA anticoagulant. The milk was collected from the maternal breast or abdominal nip ple after oxytocin was dosed intraperitoneally at 0.5 u nits/kg body weight. Aprotinin was added to the milk and blood for a final concentration of 1000 KIU/ml. Total radioactivity, immunoreactive radioactivity and trichloroacetic acid (TCA) -precipitable radioactivity were measured as described below.
For the high-performance liquid chromatography (HPLC) analysis of radioactivity in the milk, lactating rat were given an intravenous bolus at 40ug/kg (13.0 MBq/kg). About 1 ml of milk was collected 5 min and 2 h after dosing under light ether anaesthesia.
7. Determination of Radioactivity 1) Total Radioactivity Fifty ul of maternal blood and plasma samples, 100 pl of fetus (18th day of gestation) blood and plasma sam ples, 100 ul of amniotic fluid (18th day of gestation), the organ or tissue samples (50-300 mg) and 10 or 20 ul of milk samples were combusted in a sample oxidizer (ASC-113; Aloka). The radioactivity in each sample was measured by liquid scintillation counter (LSC, LS3801 or LS6000; Beckman). The counting efficiency was assessed by the external standard method.
2) TCA-Precipitable Radioactivity in Milk One thousand ul of 15% (w/v) TCA and 500 ul of dis tilled water were added to 10 or 20 ul of milk samples. The mixture was vigorously shaken and centrifuged at 13,000 g for 5 min. After the supernatant was aspirated, the precipitate was suspended in 200 ul of distilled water, combusted and the radioactivity was measured with the LSC.
3) Immunoreactive Radioactivity in Plasma and Milk
Immunoreactive radioactivity in maternal and fetal plasma were determined according to the methods in a previous report.4>
Immunoreactive radioactivity in the milk was deter mined according to modified plasma methods. Twenty ul of milk sample and 100 ul of 10 mM phosphate buffer sa line (pH 7.4) containing 0.5% Tween 80, 1% BSA and 0.1% sodium azide (buffer) or 20 ul of standard (blank milk) and 100 ul of 3H-SK-896 standard solution pre pared with buffer (0.050, 0.10, 0.20, 0.50, 1.0, 2.0 and 5.0 ng/ml) were added to the assay tube. Then, 100 ul of rabbit anti-human motilin antiserum at 1/100 dilution with buffer was added and incubated for 48 h at 4°C. Also, for the determination of the nonspecific binding of radioactivity, the samples which added 100 ul of buffer in female on the 12th day of gestation at a dose of 100 pg/kg 1; amniotic fluid, 2; blood, 3; bone marrow, 4; brain, 7; fetal membrane, 8; fetus, 9; gastric wall, 10; heart, 11; intes tinal wall, 12; kidney, 13; liver, 15; lung, 16; pancreas, 17; salivary gland, 18; spleen, 19; placenta, 20; thymus, 21; uterus.
instead of the antiserum were prepared. Antibody bound 3H-SK-896 was precipitated using 100µl of sheep se rum and 1000#1 of 20% (w/v) polyethyleneglycol 6000. The tubes were stood for 20 min at 4°C and centrifuged for 20 min at 1,600 g. After the supernatant was aspirat ed, the precipitation was suspended in 200 ul of distilled water, combusted in a sample oxidizer and the radioac tivity was measured with the LSC. The immunoreactive radioactivity was corrected by subtracting the non specific radioactivity. The calibration curve was ana lyzed with linear regression and immunoreactive radioactivity level was obtained.
4) HPLC Analysis of Milk Radioactivity
Ten,ul of milk was mixed well with 40 ul of the ethanol /physiological saline 3 : 1 (v/v). The supernatant was in female on the 12th day of gestation at a dose of 100 pg/kg 1; amniotic fluid, 2; blood, 3; bone marrow, 4; brain, 7; fetal membrane, 8; fetus, 9; gastric wall, 10; heart, 11; intes tinal wall, 12; kidney, 13; liver, 15; lung, 17; salivary gland, 18; spleen, 19; placenta, 20; thymus, 21; uterus.
separated by centrifugation at 13,000 g for 5 min and used for the HPLC analysis. For the measurement of radioactivity in the milk, the supernatant was injected into the HPLC equipped with a column of u Bondasphare (5 pm, 3.9 mm x 150 mm; Waters). Separations were performed using a linear gradient from 20 to 40% B in 20 min at the flow rate of 1.0 ml/min with fractions collect ed every 30 sec for 60 min. The mobile phases used were A, 50 mM sodium perchlorate (pH 7.0) and B, acetoni trile. Five ml of scintillators (ACS II, Amersham) was added to each fraction and the radioactivity was meas ured. Absorbance at 280 nm of SK-896 was used as a marker of the elution volume of 3H-SK-896.
Calculations
Plasma and milk concentrations [C; nanogram equiva lents of SK-896 (ng eq.) /ml] were calculated as follows:
C Rs = 60xSwxSR Where, Rs: radioactivity measured in the sample (dpm), SW: the real sample volume (MI), SR: the specific radioactivity of administered 3H-SK-896 (Bq/ng). However, the sum of the peak fractions was used as a Rs value of the 3H-SK-896 in milk that were analyzed by the HPLC.
Results
Whole-Body Autoradiography
Whole-body autoradiograms after intravenous bolus injection of female rats on the 12th and 18th day of gesta tion with 3H-SK-896 are shown in Fig.  1 and Fig. 2 On the other hand, in female rats on the 18th day of gestation, the distribution profiles of the radioactivity were the same as those of rats on the 12th day of gesta tion, except for a little radioactivity in the fetus 2 min and a high radioactivity in the fetus eyeball 24 h after dosing.
Moreover, no localization of the radioactivity was seen in the genital organs. Fig. 2-1 Autoradiograms showing the distribution of radioactivity after a single intravenous bolus injection of 3H-SK-896 in female on the 18th day of gestation at a dose of 100 pg/kg 1; amniotic fluid, 2; blood, 3; bone marrow, 4; brain, 5; brain (fetus), 7; fetal membrane, 8; fetus, 9; gastric wall, 10; heart, 11; intestinal wall, 12; kidney, 13; liver, 14; liver (fetus), 15; lung, 16; pancreas, 17; salivary gland, 18; spleen, 19; placenta, 20; thymus, 21; uterus.
Feto-Placental
Transfer Study The tissue levels of total radioactivity after in travenous bolus injection of female rats on the 12th and 18th day of gestation with 3H-SK-896 are shown in Ta  ble I and Table II , respectively. Also, the percentages of plasma immunoreactive radioactivity to plasma total radioactivity in the rats on the 18th day of gestation are shown in Table III. In female rats on the 12th day of gestation, the radioactivity levels in the uterus, ovary and placenta were 15.8-32.4% of that in the maternal plasma 2 min after administration. The radioactivity in the fetus was 3.60% of that in the maternal plasma. The radioactivity levels in the uterus, ovary and placenta 30 min after ad ministration were 2.15-2.88 times higher than that in the maternal plasma. The radioactivity in the fetus was 96.0 in female on the 18th day of gestation at a dose of 100 pg/kg 1; amniotic fluid, 2; blood, 3; bone marrow, 4; brain, 5; brain (fetus), 6; eyeball (fetus), 7; fetal membrane, 8; fetus, 9; gastric wall, 10; heart, 11; intestinal wall, 12; kidney, 13; liver, 15; lung, 17; salivary gland, 18; spleen, 19; placenta, 20; thymus. of that in the maternal plasma.
The radioactivity lev els of uterus, ovary and placenta 24 h after administra tion were 1.43-1.63 times higher than that in the mater nal plasma. The radioactivity in the fetus was 95.9% of that in the maternal plasma. The radioactivity distribut ed in a fetus 2, 30 min and 24 h after administration ac counted for 0.001, 0.002 and 0.003% of the dose, respec tively.
In female rats on the 18th day of gestation, the radioactivity levels of the uterus, ovary and placenta were 20.2-25.3 °o of that in the maternal plasma 2 min after administration. Radioactivity levels in the fetus and fetal plasma were 6.30 and 5.69o, respectivery, of that in the maternal plasma, while the levels in the fetal or gans and tissues were 8.04-9.82%, respectively, of that in the maternal plasma. No radioactivity was detected in the amniotic fluid. Although the percentage of plasma immunoreactive radioactivity to plasma total radioactivi ty in the maternal was 89.8%, the plasma immunoreac tive radioactivity in the fetus was below a lower limit of determination (0.050 ng/ml). The radioactivity levels of uterus, ovary and placenta 30 min after administration were 1.34-1.89 times higher than that in the maternal plasma. The levels in the fetus and fetal plasma were 149 and 62.3% of that in the maternal plasma, respective ly. The radioactivity levels of the fetus organs and tis sues were 1.30-2.11 times higher than that in the mater nal plasma, and the level in the amniotic fluid was 5.58% (n = 2) of that in the maternal plasma. Although the per centage of plasma immunoreactive radioactivity to plas ma total radioactivity in the maternal was 18.9%, the plasma immunoreactive radioactivity in the fetus was be low a lower limit of determination. The radioactivity lev els of uterus, ovary and placenta 24 h after administra tion were 0.976-1.24 times higher than that in the mater nal plasma. The radioactivity in the fetus and fetal plas ma were 108 and 38.6% of that in the maternal plasma. The radioactivity levels of the fetal organs and tissues were 0.972-1.74 times higher than that in the maternal plasma. The radioactivity in the amniotic fluid was 13.9 of that in the maternal plasma. The radioactivity dis tributed to a fetus 2, 30 min and 24 h after administration accounted for 0.204, 0.642 and 0.877°/ of the dose, respectively, and the total radioactivity transferred to fetuses on the 18th day of gestation was higher than that on the 12th day of gestation.
Milk Transfer Study
Total and immunoreactive radioactivity in the plasma, and total, immunoreactive and TCA-precipitable radioactivity in the milk after intravenous bolus injection of lactating rats are shown in Table IV .
The total radioactivity level in the milk reached a max imum of 36.7 ng eq./ml 6 h after administration. The total radioactivity in the milk was higher in comparison with that in the plasma thereafter 1 h after administra tion, and it reached a maximum of 9.27 times higher at 6 h. TCA-precipitable radioactivity level in the milk reached a maximum of 20.5 ng eq./ml 6 h after adminis tration. The concentration-time pattern of TCA-precipit able radioactivity in the milk was the same as that of total radioactivity. On the other hand, immunoreactive radioactivity in the milk was detected 15 and 30 min af ter dosing and showed the concentration 0.653 (n=3) and 1.13 ng eq./ml (n=2), respectively. The im munoreactive radioactivity levels of the milk 15 and 30 min after dosing were 0.227 and 1.59 (n=2) times higher than that in the plasma, respectively. Also, the percentage of milk immunoreactive radioactivity to milk total radioactivity showed a maximum 53.5% (n=2) at 15 min.
HPLC Analysis of Milk Radioactivity
The HPLC chromatograms of the milk supernatant 5 min and 2 h after intravenous bolus injection of lactating rats are shown in Fig. 3 . In the milk used for the HPLC analysis, the percentage of milk immunoreactive radioactivity to milk total radioactivity at 5 min and 2 h were 28.7% and 1.05%, respectively. After administra tion, six peaks at 5 min and three peaks at 2 h were de tected, and peak 3 was assumed to be 3H-SK-896. The percentages of 3H-SK-896 in the milk to milk total radioactivity at 5 min and 2 h were 8.58% and 1.01%, respectively.
Discussion
In the present study, the feto-placental transfer and excretion to the milk of SK-896 was investigated after single intravenous administration of 3H-SK-896 in rats.
The radioactivity levels of the fetus on 12th and 18th day of gestation 2 min after administration were 3.60% Table IV Plasma and milk radioactivity levels after single intravenous bolus injection of 3H-SK-896 in lactating rats at a dose of 4µg/kg Each value represents the mean±S.E. of three rats (*1 : n=1, *2 : n=2). ug/kg and 6.30% of that in the maternal plasma, respectively, and a little radioactivity was transferred to the fetus. However, on the 18th day of gestation, no immunoreac tive radioactivity was detected in the fetal plasma, while 89.8% of total radioactivity 2 min after administration had immunoreactivity in maternal plasma, indicating that SK-896 or immunoreactive metabolites do not transfer to the fetus. Although the presence of the im munoreactive radioactivity in the fetus on the 12th day of gestation is not clear, it is known that feto-placental transfer of the drug generally increases in the pregnancy anaphase. Actually in the present study, the total radioactivity transferred to fetuses on the 18th day of gestation was higher than that on the 12th day of gesta tion, so SK-896 or immunoreactive metabolites also were presumed not to transfer to the fetus on the 12th day of gestation. Also, the radioactivity in the genital or gans was low value: 15.8-32.4% of that in the maternal plasma, reflecting almost no transfer of SK-896 to the genital organs. On the other hand, 30 min after adminis tration, the radioactivity levels of the fetus on 12th and 18th day of gestation increased further, reaching 96.0% and 149% of those in the maternal plasma, respectively. However, no plasma immunoreactive radioactivity was detected in the fetus on the 18th day of gestation, while 18.9 °/ of total radioactivity had immunoreactivity in maternal plasma. These findings suggest that the in crease in total radioactivity in the fetus resulted from the fact that metabolites without immunoreactivity were in corporated into the fetus and used for protein synthesis. Also, 24 h after administration, the high radioactivity seen in the fetal eyeball on the 18th day of gestation in the ARG study was conceivable for the same reason. After intravenous bolus injection of lactating rats with 3H-SK-896 , the immunoreactive radioactivity was de tected in the milk at 15 and 30 min. To confirm the im munoreactive radioactivity in the milk, HPLC analysis of the milk was conducted 5 min and 2 h after intravenous administration at the higher dose, and the 3H-SK-896 peak was observed. These results indicate that 3H-SK 896 is transferred to the milk. The HPLC analysis rev ealed 8.58% of total radioactivity was 3H-SK-896 frac tion at 5 min after administration, much lower than that of the immunoreactive radioactivity (28.7%) . This would suggest that immunoreactive metabolites also transfer other than 3H-SK-896 to the milk. Although im munoreactive radioactivity in the milk reached the maxi mum (1.59 times higher than that in the plasma) 30 min after administration, the fast disappearance of the im munoreactive radioactivity in the milk and undetectable levels 1 h after administration suggested that SK-896 did not accumulate in milk. On the other hand, the per centage of TCA-precipitable radioactivity to total radioactivity in the milk increased with time, reaching 68.5% 24 h after administration. Thus, the metabolites were incorporated in the high molecular weight compo nent in the milk under a galactosis process. This was also observed with rhG-CGS5> and rt-PA3> which iodinated tyrosine-terminal residue with 125I, and not a phenomen on specific to 3H-SK-896.
In conclusion, the present study showed that 3H-SK 896 or immunoreactive metabolites are not transferred to the fetus after intravenous administration to gestating female rats. Also, a little 3H-SK-896 and some im munoreactive metabolites were transferred to the milk after intravenous administration to lactating rats, but they quickly disappeared and did not accumulate in the milk.
